Thermo Fisher Scientific's $13.6 Billion Acquisition of Life Technologies Boosts Flagging M&A Numbers May 01, 2013 | Press Release
Burrill Securities Launches Institutional Breakthrough Series April 29, 2013 | Press Release
Big Biotech Outpaces Big Pharma, Burrill & Company says April 16, 2013 | Press ReleaseSee all News
Thomas GerlachDirector, Brazil
Thomas Gerlach joined Burrill & Company in 2012 after nearly 20 years in the pharmaceutical industry in different positions within multinational companies where he was involved in drug development, brand management. From 2002 to 2010 he served as general manager of Actelion Pharmaceuticals do Brasil, the Brazilian subsidiary of Actelion. There he laid the foundation for the company’s Latin American operations. He originally joined Actelion as a project manager in Switzerland in 2000. Prior to that, Mr. Gerlach held positions with Novartis, Knoll AG, and BASF Pharma.
He has been a visiting scholar at Michigan State University where he worked on research projects in the field of retinoids. He holds a Ph.D. in Pathobiochemistry from and a degree in Chemistry (Staatsexamen) from the University of Mainz, Germany, and a masters in biology from the University of Mainz. He is fluent in German, English, Portuguese, and has some understanding of Spanish.